Breast Cancer

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Real-world data supported the clinical effectiveness of first-line palbociclib plus endocrine therapy in HR-positive, HER2-negative breast cancer.

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Experts explore how advances in systemic therapy are helping personalize and de-escalate breast cancer treatment.

Experts discuss how coordinated clinical trial participation enables safer treatment de-escalation and advances breast cancer care through research efforts.

Experts discuss how coordinated tumor board reviews enhance continuity of care, treatment personalization, and patient confidence after breast cancer surgery.

Experts discuss how involving plastic surgeons and genetic counselors early in breast cancer care helps guide personalized surgical decisions.

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Panelists discuss how treatment algorithms should differentiate between primary and secondary endocrine resistance, disease burden, and mutation status while looking forward to future combinations with oral selective estrogen receptor degraders (SERDs) and next-generation PIK3CA inhibitors with improved toxicity profiles to enable more effective precision medicine approaches.

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

Experts discuss the importance of early multidisciplinary collaboration in breast cancer care, particularly involving radiation oncology at diagnosis.

Experts discuss how a multidisciplinary clinic streamlines care and improves treatment planning for patients with newly diagnosed breast cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.